FADS2 and exocrine pancreatic carcinoma: Also, compared to the control group, pretreatment TMG significantly enhanced ZEB1, O-GlcNAcylation, and FADS2 protein expression levels in the subcutaneous pancreatic carcinoma tissues (Figure 7G).